## LIN: Linde plc - XLB: Basic Materials

### Executive Summary

No thesis match: MRS_20 -3.0% below STRENGTH zone (4.0-10.0%); PEG 1.93 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($395.83)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_20 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 5, Bearish: 0)

**1. Groupe la Francaise Raises Position in Linde PLC $LIN**
- Source: MarketBeat | 20251203T102422 | Somewhat-Bullish | Relevance: 100%
- Groupe la Francaise increased its stake in Linde PLC by 29.4% in Q2, making it its 12th largest holding. The article details institutional ownership, recent analyst ratings, financial performance including EPS and revenue, and dividend information for Linde PLC.

**2. Clifford Chance advises Linde plc on €1.75 billion triple series bond issue**
- Source: Legal Desire Media and Insights | 20251201T073629 | Somewhat-Bullish | Relevance: 100%
- Global law firm Clifford Chance advised Linde plc on a successful €1.75 billion triple tranche bond issuance. The bonds were issued under Linde plc's €20 billion Debt Issuance Programme and comprised three series with different maturities and coupons. A syndicate of international banks participated in the transaction.

**3. Linde (NASDAQ:LIN) Sets New 1-Year Low - Time to Sell?**
- Source: MarketBeat | 20251203T171259 | Somewhat-Bearish | Relevance: 100%
- Linde (NASDAQ:LIN) has hit a new 52-week low, trading as low as $404.27, well below its moving averages, despite analysts maintaining a "Buy" rating with an average target of $508.83. The company recently reported a slight earnings beat, strong net margin, and issued FY2025 EPS guidance, while also announcing a quarterly dividend. Institutional investors have made various adjustments to their holdings in the stock.

**4. CICC Initiates Coverage of Linde (LIN) with Outperform Recommendation**
- Source: Nasdaq | 20251203T140200 | Bullish | Relevance: 100%
- CICC has initiated coverage of Linde (LIN) with an Outperform recommendation, projecting a 25.65% upside from its current price, with an average one-year price target of $513.64/share. The report highlights increased projected annual revenue of 10% and non-GAAP EPS of 15.47. Institutional ownership data shows 3,444 funds with positions in Linde, indicating a bullish outlook with a put/call ratio of 0.84.

**5. This Linde Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday**
- Source: Benzinga | 20251203T090100 | Bullish | Relevance: 100%
- This article details five new analyst initiations for Wednesday, December 3, 2025, highlighting companies like Traws Pharma, Compass Therapeutics, Linde, Pelthos Therapeutics, and Oculis Holding. Analysts from HC Wainwright & Co., Canaccord Genuity, CICC, and LifeSci Capital initiated coverage with Buy or Outperform ratings and specific price targets. Linde plc received an Outperform rating with a $510 price target from CICC.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 0, Lowers: 4)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-03 | CICC | $510 | $0 | 0% |
| 2025-11-11 | UBS | $500 | $507 | -1% |
| 2025-11-06 | RBC Capital | $540 | $576 | -6% |
| 2025-11-03 | Citigroup | $520 | $535 | -3% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-03 | CICC | init | Outperform |
| 2025-11-11 | UBS | up | Buy |
| 2025-11-06 | RBC Capital | main | Outperform |
| 2025-11-03 | Citigroup | main | Buy |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_BUYING** |
| Buys | 3 ($1.00M) |
| Sells | 0 ($0.00M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 36.9% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 7 / 3 |

**Top Holders:**
- Vanguard Group Inc: 9.2% (-0.1%)
- Blackrock Inc.: 7.6% (+0.3%)
- State Street Corpora: 4.0% (+0.9%)
- JPMORGAN CHASE & CO: 3.7% (+100.1%)
- FMR, LLC: 2.6% (+4.2%)

### Key Risks

1. Long-term trend broken: trading 10.6% below SMA200.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 1.93 elevated, pricing in significant growth expectations. Forward P/E 22.9x stretched relative to 9% growth. Quality metrics strong (margin 21%). Balance sheet: $1.7B free cash flow. Analyst sentiment negative (4 target cuts vs 0 raises). Insider buying signal ($1.0M), management confidence. Institutional flow bullish (7 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $199.2B |
| Beta | 0.86 |
| 52W Range | $387.78 - $486.38 |
| Short Interest | 1.8% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.93 |
| Forward P/E | 22.9 |
| Current P/E | 24.9 |
| YoY Growth | 8.6% |
| EPS Direction | STABLE |

### Technicals

MRS_20 stable at -3.0% (minimal 5-day change). Below STRENGTH zone by 7.0pp (needs >4.0% for momentum thesis). Underperforming sector by 3.5pp, stock-specific weakness. Below SMA200 (0.89x), long-term trend not supportive. MACD histogram positive (0.83), confirming momentum. OFD pattern: +SBL (Volatile).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -3.02% (CS: 22) | Weak |
| RSI_14 | 34.8 | Neutral |
| MACD Histogram | 0.83 | Bullish |
| vs SMA20 | 0.985x | Below |
| vs SMA50 | 0.934x | Below |
| vs SMA200 | 0.894x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $409.15
- **Stop Loss:** $395.83 (3.3% risk)
- **Target:** $422.47 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 71
- **Position Value:** $29,049.65
- **Portfolio %:** 29.05%
- **Risk Dollars:** $950.00
- **Risk Per Trade:** 0.95%
- **Modifiers:** L1 95% | L2 100% | Combined 0.95x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 0.95x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with moderately constructive conditions. Fed dovish pivot expectations from weak jobs data and declining VIX suggest improving risk appetite, though narrow breadth at 51% indicates selective participation. Focus on quality sectors benefiting from rate cut expectations.*

### Earnings

**Next:** 2026-02-05 (Est: $4.17)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $4.18 | $4.21 | +0.8% |
| 2025Q2 | $4.04 | $4.09 | +1.4% |
| 2025Q1 | $3.92 | $3.95 | +0.7% |
| 2024Q4 | $3.92 | $3.97 | +1.2% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*